- Full year 2021 revenue was $4,765 million, an increase of 46 percent, including $1,311 million of incremental revenue from Bayer Animal Health products in 2021. Full year 2021 earnings per share (EPS) was $(0.97) (reported), or $1.05 (adjusted).
- Fourth quarter 2021 revenue was $1,113 million, a decline of 2 percent. Excluding the unfavorable impact of $60 million of previously disclosed items that benefited the fourth quarter of 2020 and the unfavorable impact of foreign exchange rates, fourth quarter 2021 revenue increased 4 percent. Fourth quarter 2021 EPS was $(0.20) (reported), or $0.21 (adjusted), an increase of 70 percent as reported and 75 percent on an adjusted basis.
- Providing financial guidance for the full year 2022 with revenue of $4,745 to $4,800 million, representing growth on a reported basis at the midpoint and 2 to 3 percent growth on a constant currency basis, and diluted EPS of $0.01 to $0.07 on a reported basis, or $1.18 to $1.24 on an adjusted basis.
- Significant innovation progress in 2022: Innovation revenue expected to contribute $120 to $160 million; expect 7 approvals and launches and 5 to 7 regulatory submissions in major markets, including up to two differentiated pet health potential blockbusters.
- Providing financial guidance for the first quarter 2022 with revenue of $1,200 to $1,230 million, and diluted EPS of $0.01 to $0.07 on a reported basis, or $0.33 to $0.38 on an adjusted basis.
GREENFIELD, IN (February 24, 2022) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2021, and provided initial guidance both for the first quarter and full year 2022.
